Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access Program of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva

NCT07301450 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT07301450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07301450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access Program of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva
Lead sponsor
Regeneron Pharmaceuticals
Phase
Expanded access
Overall status
Temporarily not available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

fibrodysplasia ossificans progressiva (fop)